Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G17DT + cisplatin + 5-fluorouracil
- Development stage
- Phase 3
- Lead developer
- Symphogen
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
G17DT + cisplatin + 5-fluorouracil is an investigational combination regimen for advanced gastrointestinal cancers, particularly advanced gastric cancer. G17DT (also known as Gastrimmune or PAS) is a peptide-conjugate cancer vaccine that generates antibodies against gastrin-17, a hormone that stimulates tumor growth via the cholecystokinin-2 (CCK-B) receptor. The addition of cisplatin (a DNA crosslinking platinum compound) and 5-fluorouracil (a pyrimidine analog antimetabolite) forms a chemotherapeutic backbone where G17DT acts as immunotherapy by blocking gastrin-driven tumor proliferation, while cisplatin and 5-fluorouracil induce cytotoxicity and inhibit DNA and RNA synthesis, respectively. This combination has been studied in phase II and III clinical trials for stage IV gastric adenocarcinoma, and it has received orphan drug and fast track designations in multiple jurisdictions[1][2][3][4].
- Brand names
- Gastrimmune
- Other names
- anti-gastrin 17 immunogen + cisplatin + 5-fluorouracilPAS + cisplatin + 5-fluorouracilG17DT immunogen + cisplatin + 5-fluorouracil
02
Targets
CCK2R (Cholecystokinin 2 Receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on G17DT + cisplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G17DT + cisplatin + 5-fluorouracil.